Eyepoint Pharmaceuticals Q2 2024 Earnings Report

Eyepoint Pharmaceuticals EPS Results

• Actual EPS: -$0.58
• Consensus EPS: -$0.55
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

Eyepoint Pharmaceuticals Revenue Results

• Actual Revenue: $9.48 million
• Expected Revenue: $11.61 million
• Beat/Miss: Missed by -$2.13 million
• YoY Revenue Growth: N/A

Eyepoint Pharmaceuticals Announcement Details

• Quarter: Q2 2024
• Date: 8/7/2024
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 7, 2024
• Conference Call Time: 7:15AM ET

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is a clinical‐stage biopharmaceutical company dedicated to developing and commercializing therapies for the treatment of ocular diseases. The company focuses on sustained‐release drug delivery technologies designed to address chronic and acute conditions affecting the posterior segment of the eye. Eyepoint’s proprietary platform aims to improve patient compliance and clinical outcomes by reducing the frequency of intravitreal injections.

Eyepoint’s lead product, YUTIQ®, is a non‐biodegradable intravitreal implant that delivers fluocinolone acetonide over a period of up to 36 months for the treatment of non‐infectious uveitis affecting the posterior segment of the eye. The company’s second approved therapy, DEXYCU®, is a low‐volume, injectable suspension of dexamethasone formulated for the treatment of postoperative inflammation following cataract surgery. Both products leverage Eyepoint’s expertise in ocular formulation science and aim to set new standards in sustained ocular drug delivery.

Founded in 2014 as a spin‐out from pSivida Corporation’s ophthalmic drug delivery operations, Eyepoint Pharmaceuticals built its commercial infrastructure in the United States and secured FDA approvals for its lead candidates. The company has continued to advance its pipeline, exploring additional indications for its existing implants and investigating next‐generation delivery platforms. Clinical development efforts include trials in diabetic macular edema and other retinal disorders, as the company seeks to expand its therapeutic footprint.

Headquartered in Watertown, Massachusetts, Eyepoint’s commercial organization supports a growing network of retina specialists, ophthalmologists and surgical centers across the U.S. The executive leadership team brings decades of combined experience in pharmaceutical research, regulatory affairs and specialty sales. As Eyepoint pursues regulatory filings in new territories and evaluates strategic partnerships, it remains committed to improving long‐term patient outcomes through innovative ocular therapies.